However, combined with actinomycin D (or etoposide or probably other p53 activators), the antagonists of MDM2 can sensitize cancer cells to the destruction by a patient’s own cytotoxic lymphocytes or natural killer cells, which employ FASLG on their surface to induce the death of target cells [25]. The gene discussed is TP53; the disease is cancer.